Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.109845 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.109845 32425307!7232064!32425307     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 143 (ä): 109845 Nephropedia Template TP {{tp|p=32425307|t=2020. Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19 |pdf=|usr=}}{{32425307}} gab.com Text Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32425307 #FOAvip Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14-20 days. However, about 15% of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (<65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early initiation of a specific adaptive immune response to eliminate the virus and prevent the progress to severe stages. In patients with a dysfunctional bridge adaptive immunity, the innate immune response becomes exaggerated due to the lack of feedback from the adaptive immune cells. The resultant cytokine storm is responsible for the severe lung injury leading to acute respiratory distress syndrome seen in COVID 19 patients. Mesenchymal stem cells are known to suppress overactive immune responses as well as bring about tissue regeneration and repair. This immuno-modulatory effect of MSCs could hold potential to manage a patient with severe symptoms of COVID 19 infection due to a dysfunctional adaptive immune system. Twit Text FOAVip Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32425307 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32425307 #FOAvip English Wikipedia <ref>{{Cite pmid|32425307}}</ref> Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19 #MMPMID32425307 Rao V; Thakur S; Rao J; Arakeri G; Brennan PA; Jadhav S; Sayeed MS; Rao G Med Hypotheses 2020[Oct]; 143 (ä): 109845 PMID32425307show ga Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14-20 days. However, about 15% of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (<65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early initiation of a specific adaptive immune response to eliminate the virus and prevent the progress to severe stages. In patients with a dysfunctional bridge adaptive immunity, the innate immune response becomes exaggerated due to the lack of feedback from the adaptive immune cells. The resultant cytokine storm is responsible for the severe lung injury leading to acute respiratory distress syndrome seen in COVID 19 patients. Mesenchymal stem cells are known to suppress overactive immune responses as well as bring about tissue regeneration and repair. This immuno-modulatory effect of MSCs could hold potential to manage a patient with severe symptoms of COVID 19 infection due to a dysfunctional adaptive immune system. |*Adaptive Immunity[MESH] |*Immunity, Innate[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Catalysis[MESH] |Comorbidity[MESH] |Coronavirus Infections/*immunology/therapy[MESH] |Cytokine Release Syndrome/virology[MESH] |Cytokines/immunology[MESH] |Humans[MESH] |Mesenchymal Stem Cell Transplantation[MESH] |Mesenchymal Stem Cells/*cytology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*immunology/therapy[MESH] |SARS-CoV-2[MESH] |Th1 Cells/immunology[MESH]Mesenchymal stem cells-bridge catalyst between innate and adaptive imm(epmc).pdf DeepDyve Pubget Overpricing